Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $16.00 price target on Cabaletta Bio Inc. (NASDAQ: CABA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
